Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
Previous Symbol
CUSIP30063P10
Phone608-284-5700
Debt
Debt-to-Equity Ratio0.94
Current Ratio12.08
Quick Ratio11.72
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$265.99 million
Price / Sales32.98
Cash FlowN/A
Price / CashN/A
Book Value$5.83 per share
Price / Book12.24
Profitability
EPS (Most Recent Fiscal Year)($0.99)
Net Income$-114,390,000.00
Net Margins-35.83%
Return on Equity-20.18%
Return on Assets-11.11%
Miscellaneous
Employees1,268
Outstanding Shares122,900,000
Market Cap$8.41 billion
OptionableOptionable
EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions
What is EXACT Sciences' stock symbol?
EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."
How were EXACT Sciences' earnings last quarter?
EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Tuesday, October, 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.05. The medical research company had revenue of $118.29 million for the quarter, compared to the consensus estimate of $109.33 million. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The company's revenue for the quarter was up 63.0% on a year-over-year basis. During the same period last year, the business posted ($0.23) EPS. View EXACT Sciences' Earnings History.
When is EXACT Sciences' next earnings date?
What guidance has EXACT Sciences issued on next quarter's earnings?
EXACT Sciences issued an update on its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $435-440 million, compared to the consensus revenue estimate of $428.75 million.
What price target have analysts set for EXAS?
12 brokerages have issued 12-month price targets for EXACT Sciences' shares. Their predictions range from $65.00 to $100.00. On average, they expect EXACT Sciences' share price to reach $86.0909 in the next year. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for EXACT Sciences.
What is the consensus analysts' recommendation for EXACT Sciences?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.
What are Wall Street analysts saying about EXACT Sciences stock?
Here are some recent quotes from research analysts about EXACT Sciences stock:
- 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (10/30/2018)
- 2. BTIG Research analysts commented, "5 th , data on Exact Sciences’ second case control study for its liver biomarker is scheduled to be presented at the Digestive Disease Week (DDW) conference. Recall that the biomarkers are being co-developed with the Mayo Clinic. The abstract is available on DDW’s website and preliminary details show encouraging 95% sensitivity across all stages (93% specificity in healthy controls, 86% specificity in cirrhotic controls). A liver screening test is one of a number of platforms in EXAS’ cancer pipeline and given the improving traction here, may be the second real shot on the goal, though years away. While we don’t view this as a material stock-moving event, pipeline advancement is supportive of our positive thesis on the name. We reiterate our Buy rating and $70 PT." (6/5/2018)
Has EXACT Sciences been receiving favorable news coverage?
Press coverage about EXAS stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of EXACT Sciences' key competitors?
Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).
Who are EXACT Sciences' key executives?
EXACT Sciences' management team includes the folowing people:
- Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 52)
- Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 40)
- Mr. Graham P. Lidgard, Chief Science Officer (Age 69)
- Mr. D. Scott Coward, Chief Legal Officer, Sr. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Maneesh K. Arora, Transition Consultant (Age 49)
Who are EXACT Sciences' major shareholders?
EXACT Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (3.68%), William Blair Investment Management LLC (1.90%), Alliancebernstein L.P. (1.85%), Gilder Gagnon Howe & Co. LLC (1.59%), Frontier Capital Management Co. LLC (1.29%) and Eagle Asset Management Inc. (1.00%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.
Which major investors are selling EXACT Sciences stock?
EXAS stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, OppenheimerFunds Inc., Macquarie Group Ltd., Victory Capital Management Inc., Alliancebernstein L.P., Wasatch Advisors Inc., Zweig DiMenna Associates LLC and Artemis Investment Management LLP. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.
Which major investors are buying EXACT Sciences stock?
EXAS stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, First Trust Advisors LP, Frontier Capital Management Co. LLC, Eagle Asset Management Inc., Baillie Gifford & Co., Carillon Tower Advisers Inc., Eaton Vance Management and Jennison Associates LLC. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.
How do I buy shares of EXACT Sciences?
Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EXACT Sciences' stock price today?
One share of EXAS stock can currently be purchased for approximately $71.38.
How big of a company is EXACT Sciences?
EXACT Sciences has a market capitalization of $8.41 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.
What is EXACT Sciences' official website?
How can I contact EXACT Sciences?
EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.
MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
